0V0 Stock Overview
Vimian Group AB (publ) engages in the animal health business worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Vimian Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.50 |
| 52 Week High | kr3.30 |
| 52 Week Low | kr1.76 |
| Beta | 1.52 |
| 1 Month Change | -2.77% |
| 3 Month Change | -0.04% |
| 1 Year Change | -20.19% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0V0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -3.1% | -0.6% | -1.4% |
| 1Y | -20.2% | -9.6% | 2.2% |
Return vs Industry: 0V0 underperformed the German Medical Equipment industry which returned -9.6% over the past year.
Return vs Market: 0V0 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 0V0 volatility | |
|---|---|
| 0V0 Average Weekly Movement | 7.9% |
| Medical Equipment Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 0V0 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0V0's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1,100 | Patrik Eriksson | vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
| 0V0 fundamental statistics | |
|---|---|
| Market cap | €1.35b |
| Earnings (TTM) | €9.84m |
| Revenue (TTM) | €331.73m |
137.1x
P/E Ratio4.1x
P/S RatioIs 0V0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0V0 income statement (TTM) | |
|---|---|
| Revenue | €331.73m |
| Cost of Revenue | €102.30m |
| Gross Profit | €229.43m |
| Other Expenses | €219.59m |
| Earnings | €9.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 0.019 |
| Gross Margin | 69.16% |
| Net Profit Margin | 2.97% |
| Debt/Equity Ratio | 57.4% |
How did 0V0 perform over the long term?
See historical performance and comparison